What We Do
We are a developmental stage biotechnology company primarily focused on developing and commercializing an orally delivered proprietary peptide to treat hypogonadism (low testosterone). Our goal is to recover testosterone levels safely and effectively for patients with low testosterone.
We hold an exclusive worldwide license to a McGill University, Montreal, Quebec Canada, patent (Dr. Vassilios Papadopoulos with co-inventors) which covers peptide-based agents promoting endogenous steroidogenesis and particularly the production of testosterone as well as associated therapeutic applications especially suited for the prevention, treatment and/or alleviation of symptoms associated with hypogonadism. The peptide-based agents comprise 1433ε binding motifs and are shown to limit or impede the association between the 1433ε protein and the VDAC1 protein. The license also covers corresponding screening assays for identifying further therapeutic agents for promoting endogenous steroidogenesis especially suited for the prevention, treatment and/or alleviation of symptoms associated with hypogonadism.
We have established a collaboration with the Research Institute of the McGill University Health Centre (RIMUHC), a world class facility located in Montreal, where current research and development activities are being conducted. The research team is led by Dr. Vassilios Papadopoulos, one of our founders and directors, who specializes in the biochemistry of steroids and their impact on human disease and use as biomarkers for detection of disease.
Our Management Team & Board of Directors
Mr. Richard M. Schell
CEO, President and Chairman of the Board
Dick Schell is a co-founder of the Company and has served as our Chief Executive Officer and Chairman of the Board of Directors since inception. Mr. Schell has more than 35 years of successful business experience in financial services including health care, energy and technology. Mr. Schell was the co-founder of a bank that was profitable since inception.
Mr. Duane C. Knight, Jr.
CFO & Director
Duane C. Knight, Jr. has served as our Chief Financial Officer since March, 2015. From 1999 to the present he was the owner of owner of D.C. Knight & Company, Inc., a financial and accounting consulting firm. Mr. Knight served as chief financial officer of ValveXchange, Inc., a medical device manufacturer and distributor, Neuromonics, Inc., and Denver Biomedical, Inc., all of which are medical and device manufacturers. Mr. Knight earned his BSBA degree in Accounting from Colorado State University with a Minor in Economics, and an MBA from the University of Colorado. He is a published author, speaker and a Colorado Certified Public Accountant.
Dr. Papadopoulos was named dean of the USC School of Pharmacy in fall 2016. Before joining USC, he served as executive director and chief scientific officer of the Research Institute of McGill University Health Centre in Montreal. A noted scientist and innovative leader, Dr. Papadopoulos serves on many national and international advisory committees and is an elected foreign member of the National Academies of Medicine and Pharmacy in France, fellow of the American Association for the Advancement of Science and fellow of the Canadian Academy of Health Sciences. Dr. Papadopoulos was formerly a faculty member of Georgetown University's School of Medicine in Washington D.C. and became a professor and Chairman of the Biochemistry and Molecular Biology departments, and the Director of the Biomedical Graduate Research Organization. Dr. Papadopoulos has published more than 300 articles and holds many patents and his work has been cited over 16,000 times. Dr. Papadopoulos is a graduate of the School of Pharmacy of the University of Athens, Greece, and completed his PhD in Health and Life Science at the Université Pierre et Marie Curie in Paris.
From 2009 to the present, Dr. Karatzas serves as the Director of Business Development at the Research Institute of McGill University Health Center, Montreal, Canada responsible for business development, technology transfer, commercialization, fund raising and international alliance activities. From 1994 to 2008 he held senior management positions as Vice President and Senior Vice President of R&D managing multidisciplinary teams of scientists and responsible for operations, IP strategy, technology transfer and part of senior management of NEXIA Biotechnologies Inc. during their initial public offering. He also held senior management positions at Gene Pharming Europe, AgroCultures, Pharmathene Inc. Dr. Karatzas has 47 peer review publications, and is the inventor of 16 patents and he has authored 4 book chapters. Dr. Karatzas attended McGill University where he earned a M.Sc., (Hon.) in Muscle Biochemistry and a Ph.D., in Molecular Biology (Animal Endocrinology) and has completed McGill's Executive Development Course MiniMBA.